JWA
BHVN

JFS Wealth Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

JFS Wealth Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14
Closed -$2K – 2023
2022
Q3 		$2K Hold
14
– – ﹤0.01% 1456
2022
Q2 		$2K Sell
14
-7
-33% -$894 ﹤0.01% 1443
2022
Q1 		$2K Buy
21
+8
+62% +$998 ﹤0.01% 1553
2021
Q4 		$2K Buy
+13
New +$1.65K ﹤0.01% 1221

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

JFS Wealth Advisors's BHVN Position: Q4 2022 in Review

JFS Wealth Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 14 shares — an estimated $2K sold.

JFS Wealth Advisors first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $2K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • JFS Wealth Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • JFS Wealth Advisors sold 14 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $2K.
  • JFS Wealth Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • JFS Wealth Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on JFS Wealth Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.